Geffon 250mg Tablet

Product Introduction

Geffon 250mg Tablet is a pharmaceutical product primarily utilized in the treatment of non-small cell lung cancer (NSCLC). The active ingredient in Geffon is gefitinib, a tyrosine kinase inhibitor that specifically targets and blocks the activity of the epidermal growth factor receptor (EGFR) tyrosine kinase. This receptor is often overexpressed or mutated in various cancer cells, leading to uncontrolled cell proliferation. By inhibiting EGFR, Geffon disrupts the signaling pathways that promote cancer cell growth and survival, thereby exerting its anti-cancer effects.

Geffon 250mg is presented as a film-coated tablet, designed for oral administration. The standard dose is one tablet per day, with or without food, allowing for flexible integration into a patient’s daily routine. It is essential for patients to adhere strictly to the prescribed dosage and schedule to optimize therapeutic outcomes and minimize potential adverse effects.

Uses of Geffon 250mg Tablet

Geffon 250mg Tablet is primarily indicated for the treatment of advanced or metastatic non-small cell lung cancer in patients who have specific EGFR mutations. This medication is particularly effective in patients whose tumors have exon 19 deletions or exon 21 (L858R) substitution mutations. By targeting these specific genetic alterations, Geffon offers a more personalized treatment approach, improving efficacy and reducing unnecessary exposure to cytotoxic chemotherapy.

In addition to its use in NSCLC, ongoing research is investigating the potential application of gefitinib in other cancers that exhibit aberrant EGFR activity. However, its primary and most well-documented use remains within the context of EGFR-mutant NSCLC.

Benefits of Geffon 250mg Tablet

The primary benefit of Geffon 250mg Tablet lies in its targeted mechanism of action. By specifically inhibiting EGFR, Geffon effectively slows down or stops the proliferation of cancer cells that rely on this receptor for growth. This targeted approach often leads to better outcomes compared to traditional chemotherapy, particularly in patients with the relevant EGFR mutations.

1. Enhanced Efficacy: Clinical studies have demonstrated that gefitinib can significantly improve progression-free survival (PFS) and overall response rates in patients with EGFR-mutant NSCLC. This means that patients taking Geffon are likely to experience a longer period before the disease progresses, compared to those receiving conventional chemotherapy.
2. Improved Quality of Life: Geffon is generally well-tolerated compared to traditional chemotherapy regimens. Patients often experience fewer and less severe side effects, which can significantly improve their quality of life during treatment. The convenience of oral administration also contributes to a better patient experience.
3. Personalized Therapy: The ability to tailor treatment based on genetic testing for EGFR mutations represents a significant advancement in oncology. By selecting patients who are most likely to benefit from Geffon, healthcare providers can deliver more effective and efficient care.
4. Reduced Need for Hospital Visits: As an oral medication, Geffon reduces the need for frequent hospital visits required for intravenous chemotherapy. This not only improves patient convenience but also reduces healthcare costs and resource utilization.

Side Effects of Geffon 250mg Tablet

While Geffon 250mg Tablet is generally well-tolerated, it is not without potential side effects. Patients should be monitored closely, and any adverse effects should be managed promptly to ensure optimal treatment outcomes.

1. Common Side Effects:
   • Skin Reactions: Rash and acneiform eruptions are among the most common side effects. These skin reactions are generally mild to moderate in severity and can often be managed with topical treatments or dose adjustments.
   • Diarrhea: Another frequent side effect, diarrhea, can range from mild to severe. It is crucial to manage this symptom effectively to prevent dehydration and other complications.
   • Nausea and Vomiting: These gastrointestinal symptoms are relatively common but can often be controlled with antiemetic medications.
2. Serious Side Effects:
   • Interstitial Lung Disease (ILD): Although rare, ILD is a potentially life-threatening side effect associated with gefitinib. Symptoms include shortness of breath, cough, and fever. Patients should be advised to report any respiratory symptoms immediately.
   • Liver Toxicity: Elevated liver enzymes have been observed in some patients. Regular monitoring of liver function tests is recommended to detect hepatotoxicity early.
   • Ocular Toxicity: Eye problems such as conjunctivitis and keratitis can occur. Patients should report any visual disturbances to their healthcare provider promptly.

References

Disclaimer

Singhla Medicos’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on Singhla Medicos. Our mission is to support, not replace, the doctor-patient relationship.